Abstract Psychiatric illnesses are disabling disorders with poorly understood underlying pathophysiologies. However, it is becoming increasingly evident that these illnesses result from disruptions across whole cellular networks rather than any particular monoamine system. Recent evidence continues to support the hypothesis that these illnesses arise from impairments in cellular plasticity cascades, which lead to aberrant information processing in the circuits that regulate mood, cognition, and neurovegetative functions (sleep, appetite, energy, etc.). As a result, many have begun to consider future therapies that would be capable of affecting global changes in cellular plasticity to restore appropriate synaptic function and neuronal connectivity. MicroRNAs (miRNAs) are non-coding RNAs that can repress the gene translation of hundreds of their targets and are therefore well-positioned to target a multitude of cellular mechanisms. Here, we review some properties of miRNAs and show they are altered by stress, glucocorticoids, mood stabilizers, and in a particular psychiatric disorder, schizophrenia. While this field is still in its infancy, we consider their potential for regulating behavioral phenotypes and targeting key predicted signaling cascades that are implicated in psychiatric illness. Clearly, considerable research is required to better determine any therapeutic potential of targeting miRNAs; however, these agents may provide the next generation of effective therapies for psychiatric illnesses.
Introduction
Psychiatric disorders such as schizophrenia, bipolar disorder (BPD), and major depressive disorder (MDD) are debilitating afflictions, and present a substantial burden to society. These diseases frequently prevent individuals from leading independent lives, consume considerable resources, and are chronic, lifelong, and potentially life threatening. Collectively, they are heterogeneous with variable phenotypes, which make them challenging to diagnose prior to the onset of severe symptoms, and even more difficult to treat effectively. Furthermore, these disorders are associated with a high degree of comorbidity with other diseases, such as cardiovascular disease, obesity, thyroid problems, and diabetes (Kupfer 2005) .
Researchers have long struggled to understand the molecular basis of psychiatric disorders (Fig. 1) . In the last half-century, these diseases were predominantly thought to be due to altered levels of certain monoamines. Current research, however, supports the hypothesis that these disorders are driven by disruptions in prominent biological pathways, particularly those contributing to synaptic plasticity. While research has made substantial progress in understanding the biological underpinnings of these disorders, here we will only provide a brief overview of some key findings and general themes (for more complete overviews of MDD, BPD, and schizophrenia, respectively, see Belmaker and Agam 2008; Goodwin and Jamison 2007; Lang et al. 2007) .
Genetic, cytoarchitectural, and molecular findings all suggest that a multitude of factors influence the onset and progression of these illnesses. No particular disorder or behavioral phenotype has been shown to correlate conclusively with any individual gene variant across multiple studies. Rather, it is thought that a multitude of genetic variants contribute to a predisposed state in which certain individuals are sensitive to certain environmental conditions. In recent years, the field of epigenetics has shown that certain environmental influences can produce lasting changes in DNA that alter gene expression and can ultimately influence long-term behavior (Weaver et al. 2004 ). In addition, familial, twin, and whole genome-wide association studies have firmly established that psychiatric illnesses show some degree of genetic heritability, and many genetic risk factors are thought to confer vulnerability to the various disorders (Belmaker and Agam 2008; Sklar et al. 2008 ). Structural and functional MRI studies in individuals with psychiatric disorders have identified ventricular alterations and volumetric changes in regulatory regions such as the limbic system and prefrontal cortex, which are thought to be vital to proper mood regulation (Drevets 2000; Drevets et al. 1997 Drevets et al. , 1998 Drevets et al. , 2008 Neumeister et al. 2005) . Finally, molecular findings support several emerging themes associated with the biological underpinnings of psychiatric illnesses, including fundamental impairments in neuroplasticity (Pittenger and Duman 2008) , increased neuronal vulnerability to aberrant stimuli (Kato 2008) , and dysregulation in neurotrophic factor signaling (Duman 2004; Shaltiel et al. 2007) .
Notably, although researchers have used genetic, in vivo neuroimaging, and molecular approaches to address questions surrounding the biological underpinnings of psychiatric illnesses, these findings have yet to yield a coherent overall image of the molecular basis of associated behaviors. One emerging area of particular interest is the study of microRNAs (miRNAs). miRNAs are small (about 21-23 nucleotides in length), non-peptide-coding RNAs. These molecules are partially complementary to messenger RNAs (mRNAs); thus they bind to targeted mRNAs and either suppress translation of these mRNAs to proteins, or promote mRNA degradation. Accumulating evidence indicates that miRNAs may act as key regulators in a large number of different cellular processes, including early development, proliferation, apoptosis, metabolism, and cell differentiation. A variety of miRNAs have been found in the central nervous system (CNS), and are believed to play critical roles in brain development and structural plasticity. Evidence from a handful of recent studies suggests that miRNAs may prove to be key to our understanding of the pathophysiology and, ultimately, the therapeutics of psychiatric disorders, due to their crucial role in development and broad genetic regulatory influence. miRNAs could also serve as a unifying link between many diverse groups of findings, for instance, they influence development of prominent brain structures, and are highly responsive to medications used to treat individuals with psychiatric disorders (Zhou et al. 2008) . It is possible that they could be differentially expressed in patients with psychiatric illnesses due to genetic predisposition. It should be cautioned, however, that this field is still relatively new and additional research is warranted to elucidate their possible role in psychiatric illnesses and potential targeting for treatment.
Here, we present an overview of recent studies that have examined the biological role of miRNAs in psychiatric disorders or biological processes that are known to influence behavior. We consider the potential for targeting miRNAs for treatments by examining their response to prominent mood stabilizers, as well as their ability to regulate behavioral phenotypes and target predicted signaling cascades affecting processes such as survival and proliferation.
MicroRNAs are Regulated by Stress and Glucocorticoids
Chronic psychosocial stress is known to have adverse physiological effects that contribute to cardiovascular disease, impaired immune function, inflammatory diseases, and impaired neural function and behavior (Grippo and Fig. 1 miRNAs influence the pathophysiology of psychiatric disorders. Genetic and environmental factors can influence behavior via many possible mechanisms. These mechanisms can be modified, through epigenetics or miRNAs, or they can be more permanent changes such as with genetic polymorphisms. Together, these mechanisms contribute to varying degrees of resiliency or vulnerability. It is hypothesized that these ''predisposing'' elements couple with environmental conditions (e.g., early life stress) and lead to either healthy or dysregulated mood that persists throughout an individual's lifetime Johnson 2009; Sapolsky et al. 2000) . Glucocorticoids are one of the prominent mediators of cellular stress effects on neural function and behavior, and are known to structurally alter brain cytoarchitecture in regions that contribute to cognition, memory, and emotion. Glucocorticoids have also been shown to modify dendritic pyramidal cells and suppress gliogenesis in the prefrontal cortex (Cerqueira et al. 2005; Czeh et al. 2008; Diorio et al. 1993; Wellman 2001) , impair LTP and inhibit neurogenesis in the hippocampus, and increase synaptic excitability as well as lead to neuronal hippocampal atrophy in the amygdala (Bremner et al. 2008; Miller and McEwen 2006) . These changes may account for the impaired executive function, weakened conscious memories, and exaggerated autonomic memories that ultimately contribute to maladaptive behavioral responses to chronic psychosocial stress.
Chronic psychosocial stress produces many changes at the cellular level mediated by glucocorticoids, including compromising cellular defenses and making them more susceptible to insults (i.e., free radicals, seizures, etc.), reducing cellular energy stores, and decreasing neurogenesis. Notably, however, miRNAs are hypothesized to play a specialized role in cellular responses to stress. During the cellular stress response, miRNAs have the capacity to change from translation suppressors to activators by forming new interactions between miRNA/Argonaute complexes and RNA-binding proteins that alter their subcellular localization (Leung and Sharp 2007) . Because of this modified activity, miRNAs could provide a pivotal role in mediating cellular adaptation to stress. In particular, miRNAs have been implicated in the way cells respond to oxidative stress (Leung et al. 2006; Marsit et al. 2006) , nutrient deprivation (Bhattacharyya et al. 2006) , and DNA damage (Crosby et al. 2009; Pulkkinen et al. 2008) .
Recent data investigating the manner in which miRNAs are regulated by chronic restraint stress in Wistar-Kyoto rats found that 13 miRNAs were upregulated and three miRNAs were downregulated in the hippocampus following chronic restraint stress for 21 days (Zhou R, et al. 2009, in preparation) . Interestingly, one of these miRNAs-miR-221-targets a prominent phosphatase previously implicated in psychiatric disorders: protein phosphatase 3 (Manji et al. 2003 ) regulatory subunit B, alpha isoforms (PPP3R1 or calcineurin B). Calcineurin B is a regulatory subunit of the calcium/calmodulin-regulated protein phosphatase calcineurin. Calcineurin, in turn, comprises a 19 kDa calcium-binding protein, calcineurin B, and a 61 kDa calmodulin-binding catalytic subunit, calcineurin A. PPP3R1 was further confirmed as a target of miR-221 in hippocampal cultures treated with mimics or inhibitors of miR-221 to either suppress or enhance translation. Calcineurin B was also shown to be downregulated by this chronic stress paradigm (Zhou R, et al. 2009, in preparation) . Interestingly, there is much support in the literature for calcineurin's role in neuroplasticity (Malleret et al. 2001; Mulkey et al. 1994; Wang and Kelly 1997; Winder et al. 1998) .
Another recent study found that miR-18a downregulated glucocorticoid receptor (GR) protein in the paraventricular nucleus (PVN) in Fischer 344 (F344) but not SpragueDawley (SD) rats undergoing repeated restraint stress (Uchida et al. 2008) . Cell culture studies also demonstrated that miR-18a blocked translation of GR mRNA, and that miR-18a was upregulated in the PVN in F344 rats, but not in SD rats. Interestingly, the authors claimed that F344 rats did not show hypothalamic-pituitary-adrenal (HPA) axis habituation following 14 days of this stressor. Furthermore, the F344 rats had decreased hippocampal cell proliferation and increased anxiety-like behaviors compared with SD rats. Strain differences in GR protein levels were specific for the PVN and were not detected in the hippocampus or prefrontal cortex. The authors suggest that F344 rats may provide a good model for investigating the effects of chronic stress in situations where miR-18a confers some vulnerability to stress.
Another area where the interplay between stress and miRNAs has been explored is that of maternal care in early life, which has been shown to prime the brain to be either more or less sensitive to stress and, ultimately, to influence adult ability to adapt to stress. Two potential mechanisms that may underlie this phenomenon are (1) miRNA regulation and (2) epigenetics (Fig. 1) . Both of these processes, in turn, have been reported to modulate GR function. Epigenetic studies have noted that maternal behavior where mothers engage in a high degree of licking/grooming and arched-back nursing of their pups produces adult offspring with a more tolerant HPA axis stress response. These effects can be reversed by cross-fostering or by application of a histone deacetylase (HDAC) inhibitor (Weaver et al. 2004) , and are due to altered GR function by acetylating histones H3-K9 and the methylation of the NGFI-A consensus sequence on the exon 1(7) promoter of the GR gene (Fish et al. 2004; Weaver et al. 2004) . In humans, a very recent study found epigenetic differences in a neuronspecific glucocorticoid receptor (NR3C1) promoter between human postmortem hippocampus samples from suicide victims with a history of childhood abuse and those from either suicide victims with no history of childhood abuse or controls (McGowan et al. 2009 ).
In the context of stress research, there is some evidence that miRNAs can modulate glucocorticoids (Rainer et al. 2009 ) and GR function. One recent study found that miR-18 and miR-124a reduced GR-mediated events and decreased GR protein levels. They also inhibited the GR-response gene GILZ following overexpression of either miRNA (Vreugdenhil et al. 2009 ). Further work is needed to determine whether miR-18 or miR-124a can be modulated by early life stress or maternal care. If this were found, it would provide an example of a miRNA-influenced regulatory mechanism where early life events can have profound effects on adult behavior.
MicroRNAs Dysregulated in Psychiatric Illnesses
Research to determine the putative role that miRNAs may play in mental health is still very much in its infancy. Currently, there are no studies confirming the role of miRNAs in MDD and BPD, and just a handful of studies implicating them in schizophrenia (Table 1 ). For instance, Hansen and colleagues investigated the potential regulation of miRNA genes in schizophrenia by studying the association between schizophrenia and genetic variants of miRNA genes associated with brain expression. By analyzing 18 known SNPs within close proximity to brainexpressed miRNAs, they found two SNPs (rs17578796 and rs1700) in mir-206 and mir-198 that exhibited significant allelic association with schizophrenia ( Fig. 1) . Interestingly, a follow-up study discovered that both mir-206 and mir-198 had 15 miRNA predicted targets in common (Hansen et al. 2007 ).
In a different study, Perkins and colleagues analyzed 264 human miRNAs from postmortem prefrontal cortex of individuals with schizophrenia or schizoaffective disorder using a custom miRNA microarray. They found that 16 miRNAs were significantly regulated in the prefrontal cortex of schizophrenic patients (15 downregulated, 1 upregulated) compared to healthy controls (Perkins et al. 2007 ). Another analysis of miRNA expression in postmortem cortical gray matter from the superior temporal gyrus noted significant upregulation of let-7g and miR181b expression in schizophrenia (Beveridge et al. 2008) . Others have examined 22q11.2 microdeletions, which have previously been shown to place individuals at high risk for schizophrenia. Using mouse genetics to mimic the human 22q11.2 microdeletion, researchers found biogenic changes in brain miRNAs influenced by this microdeletion (Stark et al. 2008) .
Schizophrenia has been associated with N-methyl-Daspartate receptor (NMDAR)-mediated glutamate signaling dysfunction. Notably, a very recent finding implicates miR-219 in NMDA receptor hypofunction; NMDAR signaling blockade decreased miR-219 in the prefrontal cortex of mice. This work went on to elegantly show that in vivo inhibition of miR-219 altered behavioral responses implicated in dysfunctional NMDAR signaling. Antipsychotics (haloperidol and clozapine) prevented the pharmacological knock down of miR-219 by the NMDA antagonist dizocilpine (Kocerha et al. 2009 ). Another recent report investigated the chromosome 8p region, which has been implicated in susceptibility to neuropsychiatric disorders such as schizophrenia. Four hundred and eighty-four annotated genes are located on 8p; 21 of these are implicated as candidate genes that may contribute to neuropsychiatric disorders. Seven miRNAs are also located at 8p (Tabares-Seisdedos and Rubenstein 2009) (listed in Table 1 ). Further studies are warranted to determine the precise role that these implicated miRNAs may have in the development, progression, and treatment of schizophrenia and what common predicted targets and mechanisms may confer susceptibility.
MicroRNAs Regulate Behavioral Phenotypes
miRNA modulation has been recently shown to influence circadian rhythm in Drosophila and rodents. This is particularly relevant to the interplay between miRNAs and mood disorders because circadian rhythm is well known to be dysregulated in individuals with BPD, and may be an appropriate behavioral phenotype for that disorder (Hasler et al. 2006) . In Drosophila, a microarray platform was used to mine miRNAs differentially regulated in the adult heads of wildtype flies compared to arrhythmic clock mutant cyc01 flies. Two candidate miRNAs-miR-263a and miR263b-had a rhythmic expression pattern (low during the day and peak at night) in wildtype flies, and were constitutively expressed in the cyc01 mutant (Yang et al. 2008) .
In rodents, Cheng and Obrietan found that two miRNAs-miR-219 and miR-132-were regulated in the suprachiasmatic nucleus (SCN) by the light-inducible transcription factor cAMP response element binding protein (CREB). miR-219 was also regulated by the circadian genes CLOCK and BMAL1. Furthermore, in the mouse SCN, miR-132 and miR-219 showed a circadian expression pattern (Cheng et al. 2007 ). The functional roles of these two miRNAs were explored by manipulating their expression using antagomirs (a small, synthetic cholesterol-modified RNA that is perfectly complementary to the specific miRNA target), and determining their effect on behavioral rhythms measured via wheel running. miR-219 knockdown lengthened the circadian period, while miR-132 knockdown negatively regulated light-induced clock resetting. Taken together with the work of Kocerha and colleagues, these data are among the first to show that miRNA modulation can influence behavior. Collectively, these data also expand our understanding of the complex regulation of circadian rhythms, which appear to occur not only through transcriptional feedback mechanisms, but also via miRNA-mediated translational control. 
MicroRNAs and Their Targets as Potential Therapies to Treat Mental Illness
Because of the sparse data investigating the putative role of miRNAs in the development of novel therapeutics for psychiatric disorders, we will focus here predominantly on mood disorders. Novel, effective treatments for BPD have been lacking over the past few decades. One of the most reliable and frequently prescribed mood stabilizers, lithium, is also among the oldest in the field. While lithium is considered a ''first-line'' medication, it is only effective for approximately half of patients, has many undesirable side effects (especially at the higher doses required by many patients), and has a delayed onset of action (Keck et al. 1996) . In conjunction with these clinical observations, many researchers have attempted to elucidate the molecular alterations associated with lithium's delayed onset of action. Over the past decade, studies have identified a plethora of proteins targeted by lithium treatment, with changes reported in canonical proteins such as B-cell lymphoma 2 (Bcl-2), extracellular signal regulated kinase (ERK), brain-derived neurotrophic factor (BDNF), and glycogen synthase kinase 3 beta (GSK-3b). Broadly, lithium treatment has also been associated with enhanced neuroplasticity, improved neuroprotection, increased rates of neurogenesis, and several other changes in biological function (Chen and Manji 2006; Coyle and Duman 2003) . Overall, lithium alters a multitude of intracellular cascades, has a large number of direct and indirect targets, and induces system-wide changes (Chen and Manji 2006; Coyle and Duman 2003; Shaltiel et al. 2007 ). Thus, predicting its targets has proven challenging and, at times, almost random (though some major cascades have shown a coherent response).
In this context, it is noteworthy that miRNAs have recently emerged as key regulators of complex temporal and spatial patterns of gene/protein expression changes and, thereby, synaptic and neural plasticity. Researchers have therefore recently begun to investigate whether miRNA expression is altered by treatment with mood stabilizers. Zhou and colleagues identified eight miRNAs whose expression levels decreased in the hippocampus of rats following chronic treatment with lithium or valproate (VPA) (two structurally dissimilar mood stabilizers); one miRNA increased in response to both drugs (see Table 2 ) (Zhou et al. 2008 ). This study went on to validate that decreases in miRNA levels can elicit a concurrent increase in a predicted protein target in cell culture following exogenous application of lithium or VPA. While this work highlights that miRNAs are responsive to mood stabilizer treatment, subsequent studies are needed to validate whether targeting any of these miRNAs individually can elicit mood stabilizer-like effects in rodent models of mania or depression (see Fig. 2 ).
More broadly, regulated alteration of miRNAs could prove to have a high therapeutic potential, or at least help to explain the therapeutic effects of current mood stabilizers. Any given miRNA can have hundreds of possible messenger RNA targets, so that altering one miRNA may lead to a diverse set of alterations in downstream protein expression. Given that lithium treatment alters some miRNA levels, it is possible that these molecules serve as upstream regulators of already identified protein targets. The accuracy of bioinformatic prediction software continues to improve as models incorporate new findings surrounding the targeting mechanisms of miRNAs (Chaudhuri and Chatterjee 2007; Rajewsky 2006; Sethupathy et al. 2006) . This improvement will help researchers to efficiently determine whether the multitude of reported effects from lithium could be due to the alteration of only a handful of miRNAs.
Many mechanisms have been hypothesized to underlie current therapies for psychiatric disorders. These mechanisms include but are not limited to: cell survival, neurogenesis, enhanced neuroplasticity, calcium regulation, and enhanced mitochondrial and endoplasmic reticulum (ER) function. From a therapeutic perspective, however, the great advantage of miRNAs is their ability to target hundreds of genes that could potentially be involved in many Cell morphology (**3); cell death (**4); cellular development (**3); cell-to-cell signaling and interaction (**2); amino acid metabolism (**1) miR-144 1.70/1.58 Developmental disorder (**2); neurological disease (**5); genetic disorder (**2); Cellular movement (**6); cell morphology (**7); cellular assembly and organization (**9); cell cycle (**1); cell death (**1) RAR Activation (***9/141); Wnt/Beta-catenin signaling (***9/144); aminosugars metabolism (**4/45); ERK/MAPK signaling (**8/162); tight junction signaling (**7/135) Target prediction for miRNA targets performed using PicTar on human miRNA sequences
Pathway & functional analysis of predicted targets was performed using Ingenuity Pathway Analysis (# of predicted miRNA targets/out of entire # of molecules in top canonical pathways) * P \ 0.05; ** P \ 0.01; *** P \ 0.001
The P values for the functional analysis of predicted miRNA targets are a measure of the likelihood that the association between a set of Functional Analysis genes in our experiment and a given process or pathway is due to random chance of these processes. Ultimately this miRNA may be customtailored, or show similarity to one of those already implicated in psychiatric disorders (Table 1) , regulated by mood stabilizers (Table 2) , and/or regulated by chronic restraint stress (Zhou et al. in preparation) . Some of the predicted targets of these miRNAs are diverse genes, including mitochondrial interaction constituents (BMF), intracellular calcium signaling (calcineurin), neuronal migration in development and differentiation (DCX), and those whose influence over neural function occurs at the receptor level (GRM7). GRM7, for example, has already been implicated in anxiety-like behaviors in mice (GRM7 -/-) as well as in pharmacological studies (Cryan et al. 2003; Mitsukawa et al. 2006) . One could imagine a therapy encompassing the ''perfect'' miRNA: capable of inducing a diverse set of responses that include many of the therapeutic mechanisms discussed above and mentioned in other reviews.
Conclusion
Accumulating evidence indicates that miRNAs act as key regulators in a large number of different cellular processes such as early development, apoptosis, and metabolism, as well as cell proliferation, differentiation, and death. Several types of miRNAs have been found in the CNS, and these respond to stress and regulate morphogenesis in different cells, including neurons. Because miRNAs act on multiple plasticity cascades, targeting them may prove to be effective in the development of novel therapeutics for psychiatric disorders. While this field is still in its infancy, studies are already demonstrating that miRNAs are altered by glucocorticoids, stress, treatment with mood stabilizers, and in schizophrenia. These initial findings provide encouraging support for their relevance in the development, progression, and even treatment of psychiatric disorders. Continuing to collect data on miRNAs implicated in mental health disorders (Table 1 ) and regulated by current therapies (Table 2 ), in conjunction with animal studies that evaluate the perturbation of miRNA expression, may eventually elucidate vital mechanisms underlying the etiology of psychiatric illnesses. In this manner, future therapies may be directed at particular miRNAs of interest that can affect a multitude of targets involved in modulating mechanisms of plasticity and resiliency. The following diagram highlights current treatments known to regulate miRNAs (e.g., mood stabilizers and antipsychotics) and proposes other treatments that may be identified in the future (e.g., electroconvulsive therapy (ECT)). Targeting miRNAs may provide insight into the common and unique pathways and mechanisms of these treatments. Elucidating more miRNAs and predicted targets may reveal novel therapies that modify plasticity cascades to restore synaptic function, neuronal circuitry, and mood regulation
